Rx Safes, Inc. (OTCQB: RXSF), a healthcare technology and medical device company that develops autonomous fingerprint security products, today announced that the Company will be launching its physician-centric Doctor Direct sales program at the American College of Physicians Conference and Trade Show (ACP) in Booth 1435 on May 5 – 7, 2016 at the Walter E. Washington Convention Center in Washington D.C.
The DoctorDIRECT™ program is a simple, no-cost sales program that targets more than 150,000 physicians nationwide, offering them financial incentives and supporting materials to help patients and their families safely store prescription medications in the home. Physicians play an important role in patient education and safety when prescribing medication, and by participating in the program each physician will receive materials including custom prescription/order pads, drug abuse educational materials, as well as accreditation as a “Prescription Safety Advocate” practice, demonstrated by a shield which may be displayed in their practice. The program is designed to extend the reach of the Rx DrugSAFE product offering into the physician’s offices and their patient’s homes. The Doctor Direct Program is Sunshine Act exempt, and is both REMS and ACO compliant.
“We are excited to present the Rx DrugSAFE directly to physicians at the ACP conference,” commented Lorraine Yarde, Rx Safes’ Chief Executive Officer. “With our DoctorDIRECT™ Program, the physicians stand at the forefront of raising awareness about the drug abuse epidemic and will now have the ability to offer their patients a convenient yet secure solution to safeguard their medication at home.”
The American College of Physicians’ conference and trade show stands out as the nation’s largest gathering of more than 6,500 internal medicine specialists and subspecialists. These physicians come eager to find new products and services that will update their practices and better serve their patients.
If you are a practicing physician and are interested in finding out more about the DoctorDIRECT™ program, please visit www.rxdrugsafe.com/doctordirect and complete the registration form.
About Rx Safes, Inc.
Rx Safes, Inc. designs, develops, engineers, and markets fingerprint medical devices and security storage solutions for consumers and healthcare professionals to regulate and secure the use of controlled substances at the end user (patient and consumer) level using patented, autonomous fingerprint technology that offers greater security and tighter controls over controlled substances. The company’s innovative and unique biometric security products include biometric PCA infusion pump regulators (RxSafeDOSE), biometric needleless injectors (Rx MyDOSE) and a line of biometric security and storage products (Rx DrugSAFE product line) designed for hospitals, Emergency Service providers, professional healthcare workers, assisted living facilities, skilled nursing facilities, out-patient clinic, private physician offices, as well as consumers. It is estimated that more than 100 people die each day in the U.S. from misuse and unauthorized access to controlled substances with a social and economic price tag of over $600 billion. The Company is dedicated to providing comprehensive solutions to address the economic issues caused by drug diversion and unauthorized access to these medications, with products ranging from fingerprint medication safes, portable medical storage solutions, PCA pendants, Needle Free Injectors, locks and its revolutionary Rx SafeEHR product which is a portable HIPAA compliant electronic health record. The company works with OEM’s to improve their legacy products by integrating its patented autonomous fingerprint technology, while innovating and producing its own products. For additional information please visit www.rxdrugsafe.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company’s ability to implement its long range business plan for various applications of its technology; the Company’s ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company’s technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission.
Investor Relations Contact:
Like us on Facebook at https://www.facebook.com/rxsafes
Follow us on Twitter at https://twitter.com/RxDrugSAFE